

2006 Allergan Journal Publications

Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: Results from a phase I study in healthy subjects.

Authors: *Bello Carlo L; Sherman Laurie; Zhou Jihao [AGN]; Verkh Lev; Smeraglia John; Mount Janessa; Klamerus Karen J; Allergan*

Source: *Anti-Cancer Drugs 2006;17(3):353-8*

Utility assessment to measure the impact of dry eye disease.

Authors: *Buchholz Patricia; Steeds Carolyn S; Stern Lee S; Wiederkehr Daniel P; Doyle John J; Katz Laura M; Figueiredo Francisco C; FRCOPH; Allergan*

Source: *Ocul Surf 2006;4(3):155-61*

Consequences of glaucoma on circadian and central visual systems

Authors: *Chiquet C; Drouyer E; Woldemussie E [AGN]; Ruiz G [AGN]; Wheeler L [AGN]; Denis P; Cooper H; Romanet JP; Allergan*

Source: *J Fr Ophthalmol 2006;29(7):847-851*

Desiccating stress stimulates expression of matrix metalloproteinases by the corneal epithelium

Authors: *Corrales RM; Stern ME [AGN]; De Paiva CS; Welch J; Li DQ; Pflugfelder SC; Allergan*

Source: *Invest Ophthalmol Vis Sci 2006;47(8):3293-3302*

"Yes "No" or "Yes, but"? Multinomial modelling of NICE decision-making

Authors: *Dakin HA; Devlin NJ; Odeyemi IAO [AGN]; Allergan*

Source: *Health Policy 2006;77(3):352-367*

Apical corneal barrier disruption in experimental murine dry eye is abrogated by methylprednisolone and doxycycline

Authors: *De Paiva CS; Corrales RM; Villarreal AL; Farley W; Li DQ; Stern ME [AGN]; Pflugfelder SC; Allergan*

Source: *Invest Ophthalmol Vis Sci 2006;47(7):2847-2856*

Corticosteroid and doxycycline suppress MMP-9 and inflammatory cytokine expression, MAPK activation in the corneal epithelium in experimental dry eye

Authors: *De Paiva CS; Corrales RM; Villarreal AL; Farley WJ; Li DQ; Stern ME [AGN]; Pflugfelder SC; Allergan*

Source: *Exp Eye Res 2006;83(3):526-535*

A comparison of gatifloxacin to ciprofloxacin in the prophylaxis of Streptococcus pneumoniae in rabbits in a LASIK model

Authors: *Donnenfeld Robert S; Perry Henry D; Solomon Renee; Jensen Harold G [AGN]; Stein Jonathan; Snyder Robert W; Wittpenn John R; Donnenfeld Eric D; Allergan*

Source: *Eye & Contact Lens 2006 Jan;32(1):46-50*

Efficiency of instillation methods for prostaglandin medications. [EMBAL]

Authors: *Fiscella R; Wilensky JT; Chiang TH; Walt JG [AGN]; Allergan*

Source: *J Ocul Pharmacol Ther 2006;22(6):477-482*

Estimated comparative costs of achieving a 20% reduction in intraocular pressure with bimatoprost or latanoprost in patients with glaucoma or ocular hypertension

Authors: *Fiscella Richard; Walt John [AGN]; Allergan*
Source: *Drugs Aging 2006; 23(1): 39-47*

Costs and utilization of end-stage glaucoma patients receiving visual rehabilitation care: A US multisite retrospective study

Authors: *Gieser DK; Williams RT; O'Connell W; Pasquale LR; Rosenthal BP; Walt JG [AGN]; Katz LM; Siegartel LR; Wang LJ; Rosenblatt LC; Stern LS; Doyle JJ; Allergan*
Source: *J Glaucoma 2006; 15(5): 419-425*

Cost considerations in the medical management of glaucoma in the US: Estimated yearly costs and cost effectiveness of bimatoprost compared with other medications

Authors: *Goldberg Lawrence D; Walt John [AGN]; Allergan*
Source: *Pharmacoeconomics 2006; 24(3): 251-64*

Effect of the oestrous cycle, pregnancy and uterine region on the responsiveness of the isolated mouse uterus to prostaglandin F-2 alpha and the thromboxane mimetic U46619

Authors: *Griffiths AL; Marshall KM; Senior J; Fleming C; Woodward DF [AGN]; Allergan*
Source: *J Endourol 2006; 188(3): 569-577*

The cost-effectiveness of bimatoprost, latanoprost and timolol in treatment of primary open angle glaucoma in five European countries.

Authors: *Holmstrom Stefan [formerly AGN]; Buchholz Patricia [AGN Germany]; Walt John [AGN]; Wickstrom Jannie; Aagren Mark; Allergan*
Source: *Curr Med Res Opin 2006; 22(5): 897-905*

Pharmacology of 2-[4-(4-chloro-2-fluorophenoxy) phenyl]-pyrimidine-4-carboxamide: A potent, broad-spectrum state-dependent sodium channel blocker for treating pain states

Authors: *Ilyin VI; Pomonis JD; Whiteside GT; Harrison JE; Pearson MS; Mark L; Turchin PI; Gottshall S; Carter RB; Nguyen P [AGN]; Hogenkamp DJ; Olanrewaju S; Benjamin E; Woodward RM; Allergan*
Source: *J Pharmacol Exp Ther 2006; 318(3): 1083-1093*

Pharmacokinetics and disposition of memantine in the arterially perfused bovine eye

Authors: *Koeberle MJ; Hughes PM [AGN]; Skellern GG; Wilson CG; Allergan*
Source: *Pharm Res 2006; 23(12): 2781-2798*

Prostaglandin F₂alpha formation from prostaglandin H₂ by prostaglandin F synthase (PGFS): crystal structure of PGFS containing bimatoprost

Authors: *Komoto Junichi; Yamada Taro; Watanabe Kikuko; Woodward David F [AGN]; Takusagawa Fusao; Allergan*
Source: *Biochemistry 2006 Feb 21; 45(7): 1987-1996*

A multicenter, retrospective pilot study of resource use and costs associated with severity of disease in glaucoma

Authors: Lee PP; Walt JG [AGN]; Doyle JJ; Kotak SV; Evans SJ; Budenz DL; Chen PP; Coleman AL; Feldman RM; Jampel HD; Katz L J; Mills RP; Myers JS; Noecker RJ; Piltz-Seymour JR; Ritch RR; Schacknow PN; Serle JB; Trick GL; Allergan

Source: Arch Ophthalmol 2006 Jan; 124(1):12-19

A multicentre, retrospective study of resource utilization and costs associated with glaucoma management in France and Sweden.

Authors: Lindblom Bertil; Nordmann Jean-Philippe; Sellem Eric; Chen Enping; Gold R; Polland Werner; Williamson W; Buchholz Patricia [AGN]; Walt John G [AGN]; Groleau Danielle [AGN]; Curry Alistair; Evans Stacy J; Allergan

Source: Acta Ophthalmologica Scandinavica 2006;84(1):74-83

Changes in endocannabinoid and palmitoylethanolamide levels in eye tissues of patients with diabetic retinopathy and age-related macular degeneration

Authors: Matias I; Wang JW [AGN]; Morriello AS; Nieves A [AGN]; Woodward DF [AGN]; Di Marzo V; Allergan

Source: Prostaglandins Leukot Essent Fatty Acids 2006;75(6):413-418

Comparative toxicity of fluoroquinolone antibiotics on corneal cells in vitro.

Authors: Matsumoto Steven [AGN]; Way William [AGN]; Tarlo Kirk [AGN]; Short Brian [AGN]; Allergan

Source: Cornea 2006;25(9 Suppl 2):S1-S7

Categorizing the stage of glaucoma from pre-diagnosis to end-stage disease

Authors: Mills RP; Budenz DL; Lee PP; Noecker RJ; Walt JG [AGN]; Siegartel LR; Evans SJ; Doyle JJ; Allergan

Source: Am J Ophthalmol 2006 Jan; 141(1):24-30

Altered expression of neurotransmitter receptors and neuromediators in vernal keratoconjunctivitis

Authors: Motterle L; Diebold Y; de Salamanca AE; Saez V; Garcia-Vazquez C; Stern ME [AGN]; Calonge M; Leonardi A; Allergan

Source: Arch Ophthalmol 2006;124(4):462-468

Desiccating stress induces T cell-mediated Sjogren's syndrome-like lacrimal keratoconjunctivitis

Authors: Niederkorn JY; Stern ME [AGN]; Pflugfelder SC; De Paiva CS; Corrales RM; Gao J [AGN]; Siemasko K [AGN]; Allergan

Source: Immunology 2006 Jan; 176:3950-3957

The prostanoid EP2 receptor agonist butaprost increases uveoscleral outflow in the cynomolgus monkey

Authors: Nilsson SFE; Drecoll E; Lutjen-Drecoll E; Toris CB; Krauss AHP [AGN]; Kharlamb A [AGN]; Nieves A [AGN]; Guerra T [AGN]; Woodward DF [AGN]; Allergan

Source: Invest Ophthalmol Vis Sci 2006;47(9):4042-4049

Cost-effectiveness of monotherapy treatment of glaucoma and ocular hypertension with the lipid class of medications

Authors: Noecker RJ; Walt JG [AGN]; Allergan
Source: Am J Ophthalmol 2006 Jan; 141(1):S15-S21

Protection of RPE cells from oxidative injury by 15-deoxy-delta12,14-prostaglandin J2 by augmenting GSH and activating MAPK.

Authors: Qin Suofu [AGN]; McLaughlin Anne P [AGN]; De Vries Gerald W [AGN]; Allergan
Source: Invest Ophthalmol Vis Sci 2006; 47(11):5098-105

Carbohydrate-based micelle clusters which enhance hydrophobic drug bioavailability by up to 1 order of magnitude

Authors: Qu XZ; Khutoryanskiy VV; Stewart A; Rahman S; Papahadjopoulos-Sternberg B; Dufes C; McCarthy D; Wilson CG; Lyons R [AGN]; Carter KC; Schatzlein A; Uchegbu IF; Allergan
Source: Biomacromolecules 2006; 7(12):3452-3459

N-(4-hydroxyphenyl)retinamide induces apoptosis in human retinal pigment epithelial cells: Retinoic acid receptors regulate apoptosis, reactive oxygen species generation, and the expression of heme oxygenase-1 and Gadd153

Authors: Samuel W; Kutty RK; Nagineni S; Vijayasarathy C; Chandraratna RAS [AGN]; Wiggert B; Allergan
Source: J Cell Physiol 2006; 209(3):854-865

Twice-daily 0.2% brimonidine 0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension. A 12-month randomized trial

Authors: Sherwood MB; Craven ER; Chou C [AGN]; DuBiner HB; Batoosingh AL [AGN]; Schiffman RM [AGN]; Whitcup SM [AGN]; Combigan Study Groups I and II; Allergan
Source: Arch Ophthalmol 2006; 124(9):1230-1238

Evaluation of quality of life for patients with glaucoma

Authors: Spaeth G; Walt J [AGN]; Keener J; Allergan
Source: Am J Ophthalmol 2006; 141:S3-S14

Effects of fourth-generation fluoroquinolones on the ocular surface, epithelium, and wound healing.

Authors: Stern ME [AGN]; Gao J [AGN]; Beuerman RW; Farley W; Zhuo L; McDonnell PJ; Pflugfelder SC; Allergan
Source: Cornea 2006; 25(9 SUPPL.2):S12-S24

Evoked expression of the glutamate transporter GLT-1c in retinal ganglion cells in human glaucoma and in a rat model

Authors: Sullivan RKP; WoldeMussie E [AGN]; Macnab L; Ruiz G [AGN]; Pow DV; Allergan
Source: Invest Ophthalmol Vis Sci 2006; 47(9):3853-3859

Ocular changes after photodynamic therapy

Authors: Tzekov Radouil [AGN]; Lin Ton [AGN]; Zhang Kai-Ming [AGN]; Jackson Brittany [AGN]; Oyejide Adelekan [AGN]; Orilla Werhner [AGN]; Kulkarni Amol D [AGN]; Kuppermann Baruch D; Wheeler Larry [AGN]; Burke James [AGN]; Allergan
Source: Invest Ophthalmol Vis Sci 2006 Jan; 47(1):377-85

Recent advances in ocular therapeutics

Authors: *Whitcup Scott M [AGN]; Allergan*

Source: *Int Ophthalmol Clin 2006;46(4):1-6*

Measurement of persistence and adherence to regimens of IOP-lowering glaucoma medications using pharmacy claims data

Authors: *Wilensky J; Fiscella RG; Carlson AM; Morris LS; Walt J [AGN]; Allergan*

Source: *Am J Ophthalmol 2006;141(1 SUPPL):S28-S33*

Potential antinociceptive mechanisms of botulinum toxin. MOGLICHE ANTINOZIZEPTIVE MECHANISMEN VON BOTULINUMTOXIN

Authors: *Aoki KR [AGN]; Francis J [AGN]; Jost WH; Allergan*

Source: *Schmerz 2006 Sep;20(5):381-7*

Using translational medicine to understand clinical differences between botulinum toxin formulations

Authors: *Aoki KR [AGN]; Ranoux D; Wissel J; Allergan*

Source: *Eur J Neurol 2006;13(Suppl 4):10-19*

Understanding the role of botulinum toxin A in the treatment of the overactive bladder-more than just muscle relaxation

Authors: *Apostolidis A; Haferkamp A; Aoki KR [AGN]; Allergan*

Source: *Eur Urol Suppl 2006;5(11):670-678*

The impact of the overactive bladder on health-related utility and quality of life

Authors: *Currie CJ; McEwan P; Poole CD; Odeyemi IAO [AGN]; Datta SN; Morgan CL; Allergan*

Source: *BJU Int 2006;97(6):1267-1272*

The structure and mode of action of different botulinum toxins

Authors: *Dolly JO; Aoki KR [AGN]; Allergan*

Source: *Eur J Neurol 2006;13(Suppl 4):1-9*

A series of three sequential, randomized, controlled studies of repeated treatments with botulinum toxin type A for migraine prophylaxis

Authors: *Elkind Arthur H; O'Carroll Philip; Blumenfeld Andrew; DeGryse Ronald [AGN]; Dimitrova Rozalina [AGN]; BoNTA-024-026-036 Study Group; Allergan*

Source: *J Pain 2006;7(10):688-696*

Botulinum neurotoxin: From laboratory to bedside

Authors: *Foster KA; Bigalke H; Aoki KR [AGN]; Allergan*

Source: *Neurotox Res 2006 Apr;9(2-3):133-140*

Effectiveness of repeated treatment with botulinum toxin type A across different conditions

Authors: *Gordon MF; Barron R [AGN]; Allergan*

Source: *South Med J 2006;99(8):853-861*

Primary focal hyperhidrosis: Disease characteristics and functional impairment

Authors: Hamm H; Naumann MK; Kowalski JW [AGN]; Kutt S; Kozma C; Teale C [AGN]; Allergan
Source: *Dermatology* 2006;212(4):343-353

Cost-consequence analysis evaluating the use of botulinum neurotoxin-A in patients with detrusor overactivity based on clinical outcomes observed at a single UK centre

Authors: Kalsi V; Popat RB; Apostolidis A; Kavia R; Odeyemi IA [AGN]; Dakin HA; Warner J; Elneil S; Fowler CJ; Dasgupta P; Allergan
Source: *Eur Urol* 2006 Mar;49(3):519-27

Two protein trafficking processes at motor nerve endings unveiled by botulinum neurotoxin E

Authors: Lawrence G; Wang J; Kwo Chion CKN; Aoki RK [AGN]; Dolly OJ; Allergan
Source: *J Pharmacol Exp Ther* 2006;320(1):410-18

Inhibition by human sera of botulinum neurotoxin-A binding to synaptosomes: A new assay for blocking and non-blocking antibodies

Authors: Maruta T; Dolimbek BZ; Aoki KR [AGN]; Atassi MZ; Allergan
Source: *J Neurosci Methods* 2006;151(2):90-96

Epidemiology, prescribing patterns and resource use associated with overactive bladder in UK primary care

Authors: Odeyemi AO [AGN]; Dakin HA; O'Donnell RA; Warner J; Jacobs A; Dasgupta P; Allergan
Source: *Int J Clin Pract* 2006 Aug;60(8):949-58

Botulinum toxin type A in the prophylactic treatment of chronic tension-type headache: A multicentre, double-blind, randomized, placebo-controlled, parallel-group study

Authors: Silberstein SD; Gobel H; Jensen R; Elkind AH; DeGryse R [AGN]; Walcott JMCM [AGN]; Turkel C [AGN]; Allergan
Source: *Cephalalgia* 2006;26(7):790-800

Developing patient-reported outcome measures for pain clinical trials: IMMPACT recommendations

Authors: Turk DC; Dworkin RH; Burke LB; Gershon R; Rothman M; Scott J; Allen RR; Atkinson JH; Chandler J; Cleeland C; Cowan P; Dimitrova R [AGN]; Dionne R; Farrar JT; Haythornthwaite JA; Hertz S; Jadad AR; Jensen MP; Kellstein D; Kerns RD; Manning DC; Martin S; Max MB; McDermott MP; McGrath P; Moulin DE; Nurmikko T; Quessy S; Raja S; Rappaport BA; Rauschkolb C; Robinson JP; Royal MA; Simon L; Stauffer JW; Stucki G; Tollett J; von Stein T; Wallace MS; Wernicke J; White RE; Williams AC; Witter J; Wyrwich KW; Allergan
Source: *Pain* 2006;125(3):208-215

Pooled analysis of the safety of botulinum toxin type A in the treatment of poststroke spasticity

Authors: Turkel Catherine C [AGN]; Bowen Beta [AGN]; Liu Jingyu [AGN]; Brin Mitchell F [AGN]; Allergan
Source: *Arch Phys Med Rehabil* 2006 Jun;87(6):786-92